...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024

Settle down there, fuzzy.

 

Koo

Share
New Message
Please login to post a reply